Full-Time

Senior Data & DevOps Engineer

Posted on 5/12/2026

Deadline 5/15/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
DevOps & Infrastructure (1)
Required Skills
Redshift
Python
MySQL
R
Git
Pytorch
Apache Spark
SQL
Postgres
ETL
Data Engineering
Tableau
CloudFormation
AWS
Pandas
Scala
Requirements
  • 5+ years of hands-on experience implementing and operating data capabilities and cutting-edge data solutions, preferably in a cloud environment.
  • Expertise in designing and building real time data ingestion data pipelines in AWS.
  • Expertise in Cloud Formation.
  • Developing and using Custom Resources in CloudFormation templates.
  • Expertise in developing GitHub Workflows and integrating GitHub workflows with AWS.
  • Expertise with using boto3 APIs for Lambda, S3, Glue, Crawlers, Data Zone (preferred).
  • Expert in building APIs using AWS services.
  • In-depth knowledge and hands-on experience with AWS Glue services and AWS Data engineering ecosystem.
  • Hands-on experience developing and delivering data, ETL solutions with some of the technologies like AWS data services (Redshift, Athena, lake formation, etc.), Cloudera Data Platform, Tableau labs is a plus.
  • 5+ years of experience in data engineering or software development.
  • Create and maintain optimal data pipeline architecture, assemble large, complex data sets that meet functional / non-functional business requirements.
  • Identify, design, and implement internal process improvements: automating manual processes, optimizing data delivery, re-designing infrastructure for greater scalability, etc.
  • Strong programming skills in languages such as Python, R, PyTorch, PySpark, Pandas, Scala etc.
  • Experience with SQL and database technologies such as MySQL, PostgreSQL, Presto, etc.
  • Experience with cloud-based data technologies such as AWS, Azure, or Google Cloud Platform.
  • Strong analytical and problem-solving skills.
  • Excellent communication and collaboration skills.
  • Functional knowledge or prior experience in Lifesciences Research and Development domain is a plus.
  • Experience and expertise in establishing agile and product-oriented teams that work effectively with teams in US and other global BMS site.
  • Initiates challenging opportunities that build strong capabilities for self and team.
  • Demonstrates a focus on improving processes, structures, and knowledge within the team. Leads in analyzing current states, deliver strong recommendations in understanding complexity in the environment, and the ability to execute to bring complex solutions to completion.
Responsibilities
  • Designing, building, and maintaining the ETL pipelines, data products, evolution of the data products, and utilize the most suitable data architecture required for our organization's data needs.
  • Delivering high quality, data products and analytic ready data solution.
  • End-to-end ownership mindset, innovate and drive initiatives through completion.
  • Develop and maintain data models to support our reporting and analysis needs.
  • Optimize data storage and retrieval to ensure efficient performance and scalability.
  • Collaborate with data architects, data analysts and data scientists to understand their data needs and ensure that the data infrastructure supports their requirements.
  • Ensure data quality and integrity through data validation and testing.
  • Implement and maintain security protocols to protect sensitive data.
  • Stay up to date with emerging trends and technologies in data engineering and analytics
  • Closely partner with the Enterprise Data and Analytics Platform team, other functional data teams and Data Community lead to shape and adopt data and technology strategy.
  • Serves as the Subject Matter Expert on Data & Analytics Solutions.
  • Knowledgeable in evolving trends in Data platforms and Product based implementation.
  • Has end-to-end ownership mindset in driving initiatives through completion.
  • Mentors other team members effectively to unlock full potential.
  • Prior experience working in an Agile/Product based environment.
Desired Qualifications
  • Breadth of experience in technology capabilities that span the full life cycle of data management including data lakehouses, master/reference data management, data quality and analytics/AI ML is added advantage.
  • Fundamentals of Engineering or equal engineering certification
  • Lifesciences Research and Development domain knowledge is a plus.
  • Initiates challenging opportunities that build strong capabilities for self and team.
  • Demonstrates a focus on improving processes, structures, and knowledge within the team. Leads in analyzing current states, deliver strong recommendations in understanding complexity in the environment, and the ability to execute to bring complex solutions to completion.

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.